|
1
|
Siegel RL, Giaquinto AN and Jemal A:
Cancer statistics, 2024. CA Cancer J Clin. 74:12–49.
2024.PubMed/NCBI
|
|
2
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
3
|
Sugiura M, Sato H, Kanesaka M, Imamura Y,
Sakamoto S, Ichikawa T and Kaneda A: Epigenetic modifications in
prostate cancer. Int J Urol. 28:140–149. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu J, Dong L, Zhu Y, Dong B, Sha J, Zhu
HH, Pan J and Xue W: Prostate cancer treatment-China's perspective.
Cancer Lett. 550:2159272022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu X, Yu C, Bi Y and Zhang ZJ: Trends and
age-period-cohort effect on incidence and mortality of prostate
cancer from 1990 to 2017 in China. Public Health. 172:70–80. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang F, Wang C, Xia H, Lin Y, Zhang D, Yin
P and Yao S: Burden of prostate cancer in China, 1990–2019:
Findings from the 2019 global burden of disease study. Front
Endocrinol (Lausanne). 13:8536232022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Han B, Zheng R, Zeng H, Wang S, Sun K,
Chen R, Li L, Wei W and He J: Cancer incidence and mortality in
China, 2022. J Natl Cancer Cent. 4:47–53. 2024.PubMed/NCBI
|
|
8
|
Cao W, Chen HD, Yu YW, Li N and Chen WQ:
Changing profiles of cancer burden worldwide and in China: A
secondary analysis of the global cancer statistics 2020. Chin Med J
(Engl). 134:783–791. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Allemani C, Matsuda T, Di Carlo V,
Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ,
Estève J, et al: Global surveillance of trends in cancer survival
2000–14 (CONCORD-3): Analysis of individual records for 37 513 025
patients diagnosed with one of 18 cancers from 322 population-based
registries in 71 countries. Lancet. 391:1023–1075. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pound CR, Partin AW, Eisenberger MA, Chan
DW, Pearson JD and Walsh PC: Natural history of progression after
PSA elevation following radical prostatectomy. JAMA. 281:1591–1597.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lobo J, Barros-Silva D, Henrique R and
Jeronimo C: The emerging role of epitranscriptomics in cancer:
Focus on urological tumors. Genes (Basel). 9:5522018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rebello RJ, Oing C, Knudsen KE, Loeb S,
Johnson DC, Reiter RE, Gillessen S, Van der Kwast T and Bristow RG:
Prostate cancer. Nat Rev Dis Primers. 7:92021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barsouk A, Padala SA, Vakiti A, Mohammed
A, Saginala K, Thandra KC, Rawla P and Barsouk A: Epidemiology,
staging and management of prostate cancer. Med Sci (Basel).
8:282020.PubMed/NCBI
|
|
14
|
Feldman BJ and Feldman D: The development
of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hirst M and Marra MA: Epigenetics and
human disease. Int J Biochem Cell Biol. 41:136–146. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miremadi A, Oestergaard MZ, Pharoah PD and
Caldas C: Cancer genetics of epigenetic genes. Hum Mol Genet.
16:R28–R49. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fisk JC, Sayegh J, Zurita-Lopez C, Menon
S, Presnyak V, Clarke SG and Read LK: A type III protein arginine
methyltransferase from the protozoan parasite Trypanosoma brucei. J
Biol Chem. 284:11590–11600. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Feng Y, Hadjikyriacou A and Clarke SG:
Substrate specificity of human protein arginine methyltransferase 7
(PRMT7): The importance of acidic residues in the double E loop. J
Biol Chem. 289:32604–32616. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zurita-Lopez CI, Sandberg T, Kelly R and
Clarke SG: Human protein arginine methyltransferase 7 (PRMT7) is a
type III enzyme forming omega-NG-monomethylated arginine residues.
J Biol Chem. 287:7859–7870. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Debler EW, Jain K, Warmack RA, Feng Y,
Clarke SG, Blobel G and Stavropoulos P: A glutamate/aspartate
switch controls product specificity in a protein arginine
methyltransferase. Proc Natl Acad Sci USA. 113:2068–2073. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bedford MT and Richard S: Arginine
methylation an emerging regulator of protein function. Mol Cell.
18:263–272. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bedford MT and Clarke SG: Protein arginine
methylation in mammals: Who, what, and why. Mol Cell. 33:1–13.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang Y and Bedford MT: Protein arginine
methyltransferases and cancer. Nat Rev Cancer. 13:37–50. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu F, Wan L, Zou H, Pan Z, Zhou W and Lu
X: PRMT7 promotes the growth of renal cell carcinoma through
modulating the beta-catenin/C-MYC axis. Int J Biochem Cell Biol.
120:1056862020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Baldwin RM, Haghandish N, Daneshmand M,
Amin S, Paris G, Falls TJ, Bell JC, Islam S and Côté J: Protein
arginine methyltransferase 7 promotes breast cancer cell invasion
through the induction of MMP9 expression. Oncotarget. 6:3013–3032.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yao R, Jiang H, Ma Y, Wang L, Wang L, Du
J, Hou P, Gao Y, Zhao L, Wang G, et al: PRMT7 induces
epithelial-to-mesenchymal transition and promotes metastasis in
breast cancer. Cancer Res. 74:5656–5667. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma W, Sun X, Zhang S, Chen Z and Yu J:
Circ_0039960 regulates growth and Warburg effect of breast cancer
cells via modulating miR-1178/PRMT7 axis. Mol Cell Probes.
64:1018292022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fuhrmann J and Thompson PR: Protein
arginine methylation and citrullination in epigenetic regulation.
ACS Chem Biol. 11:654–668. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fuhrmann J, Clancy KW and Thompson PR:
Chemical biology of protein arginine modifications in epigenetic
regulation. Chem Rev. 115:5413–5461. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yao B, Zhu S, Wei X, Chen MK, Feng Y, Li
Z, Xu X, Zhang Y, Wang Y, Zhou J, et al: The circSPON2/miR-331-3p
axis regulates PRMT5, an epigenetic regulator of CAMK2N1
transcription and prostate cancer progression. Mol Cancer.
21:1192022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Beketova E, Fang S, Owens JL, Liu S, Chen
X, Zhang Q, Asberry AM, Deng X, Malola J, Huang J, et al: Protein
arginine methyltransferase 5 promotes pICln-dependent androgen
receptor transcription in castration-resistant prostate cancer.
Cancer Res. 80:4904–4917. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vieira FQ, Costa-Pinheiro P,
Ramalho-Carvalho J, Pereira A, Menezes FD, Antunes L, Carneiro I,
Oliveira J, Henrique R and Jerónimo C: Deregulated expression of
selected histone methylases and demethylases in prostate carcinoma.
Endocr Relat Cancer. 21:51–61. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Epstein JI, Egevad L, Amin MB, Delahunt B,
Srigley JR and Humphrey PA: The 2014 international society of
urological pathology (ISUP) consensus conference on gleason grading
of prostatic carcinoma: Definition of grading patterns and proposal
for a new grading system. Am J Surg Pathol. 40:244–252. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xiao WJ, Zhu Y, Zhu Y, Dai B and Ye DW:
Evaluation of clinical staging of the American Joint Committee on
Cancer (eighth edition) for prostate cancer. World J Urol.
36:769–774. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Feng Y, Sun C, Zhang L, Wan H, Zhou H,
Chen Y, Zhu L, Xia G and Mi Y: Upregulation of COPB2 promotes
prostate cancer proliferation and invasion through the MAPK/TGF-β
signaling pathway. Front Oncol. 12:8653172022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mi YY, Ji Y, Zhang L, Sun CY, Wei BB, Yang
DJ, Wan HY, Qi XW, Wu S and Zhu LJ: A first-in-class HBO1 inhibitor
WM-3835 inhibits castration-resistant prostate cancer cell growth
in vitro and in vivo. Cell Death Dis. 14:672023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jaiswal B, Agarwal A and Gupta A: Lysine
acetyltransferases and their role in AR signaling and prostate
cancer. Front Endocrinol (Lausanne). 13:8865942022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cocchiola R, Romaniello D, Grillo C,
Altieri F, Liberti M, Magliocca FM, Chichiarelli S, Marrocco I,
Borgoni G, Perugia G and Eufemi M: Analysis of STAT3
post-translational modifications (PTMs) in human prostate cancer
with different Gleason Score. Oncotarget. 8:42560–42570. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Deng X, Shao G, Zhang HT, Li C, Zhang D,
Cheng L, Elzey BD, Pili R, Ratliff TL, Huang J and Hu CD: Protein
arginine methyltransferase 5 functions as an epigenetic activator
of the androgen receptor to promote prostate cancer cell growth.
Oncogene. 36:1223–1231. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu L, Zhang X, Ding H, Liu X, Cao D, Liu
Y, Liu J, Lin C, Zhang N, Wang G, et al: Arginine and lysine
methylation of MRPS23 promotes breast cancer metastasis through
regulating OXPHOS. Oncogene. 40:3548–3563. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu Y, Li L, Liu X, Wang Y, Liu L, Peng L,
Liu J, Zhang L, Wang G, Li H, et al: Arginine methylation of SHANK2
by PRMT7 promotes human breast cancer metastasis through activating
endosomal FAK signalling. Elife. 9:e576172020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nicot C: PRMT7: A survive-or-die switch in
cancer stem cells. Mol Cancer. 21:1272022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu C, Zou W, Nie D, Li S, Duan C, Zhou M,
Lai P, Yang S, Ji S, Li Y, et al: Loss of PRMT7 reprograms glycine
metabolism to selectively eradicate leukemia stem cells in CML.
Cell Metab. 34:818–35.e7. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rodrigo-Faus M, Vincelle-Nieto A, Vidal N,
Puente J, Saiz-Pardo M, Lopez-Garcia A, Mendiburu-Eliçabe M, Palao
N, Baquero C, Linzoain-Agos P, et al: CRISPR/Cas9 screenings
unearth protein arginine methyltransferase 7 as a novel essential
gene in prostate cancer metastasis. Cancer Lett. 588:2167762024.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cheng D, He Z, Zheng L, Xie D, Dong S and
Zhang P: PRMT7 contributes to the metastasis phenotype in human
non-small-cell lung cancer cells possibly through the interaction
with HSPA5 and EEF2. Onco Targets Ther. 11:4869–4876. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen J: The Cell-cycle arrest and
apoptotic functions of p53 in tumor initiation and progression.
Cold Spring Harb Perspect Med. 6:a0261042016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Marei HE, Althani A, Afifi N, Hasan A,
Caceci T, Pozzoli G, Morrione A, Giordano A and Cenciarelli C: p53
signaling in cancer progression and therapy. Cancer Cell Int.
21:7032021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hashimoto N, Nagano H and Tanaka T: The
role of tumor suppressor p53 in metabolism and energy regulation,
and its implication in cancer and lifestyle-related diseases.
Endocr J. 66:485–496. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu J, Zhang C, Hu W and Feng Z: Tumor
suppressor p53 and metabolism. J Mol Cell Biol. 11:284–292. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang H, Xu J, Long Y, Maimaitijiang A, Su
Z, Li W and Li J: Unraveling the guardian: P53′s multifaceted role
in the DNA Damage response and tumor treatment strategies. Int J
Mol Sci. 25:129282024. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Mirzayans R, Andrais B, Kumar P and Murray
D: Significance of Wild-type p53 signaling in suppressing apoptosis
in response to chemical genotoxic agents: Impact on chemotherapy
outcome. Int J Mol Sci. 18:9282017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Madan E, Gogna R, Bhatt M, Pati U,
Kuppusamy P and Mahdi AA: Regulation of glucose metabolism by p53:
Emerging new roles for the tumor suppressor. Oncotarget. 2:948–957.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang W, Li D and Sui G: YY1 is an inducer
of cancer metastasis. Crit Rev Oncog. 22:1–11. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Li Z, Wang F, Tian X, Long J, Ling B,
Zhang W, Xu J and Liang A: HCK maintains the self-renewal of
leukaemia stem cells via CDK6 in AML. J Exp Clin Cancer Res.
40:2102021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Buontempo F, McCubrey JA, Orsini E,
Ruzzene M, Cappellini A, Lonetti A, Evangelisti C, Chiarini F,
Evangelisti C, Barata JT and Martelli AM: Therapeutic targeting of
CK2 in acute and chronic leukemias. Leukemia. 32:1–10. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Rizkallah R, Alexander KE, Kassardjian A,
Lüscher B and Hurt MM: The transcription factor YY1 is a substrate
for Polo-like kinase 1 at the G2/M transition of the cell cycle.
PLoS One. 6:e159282011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Dong X, Guo R, Ji T, Zhang J, Xu J, Li Y,
Sheng Y, Wang Y, Fang K, Wen Y, et al: YY1 safeguard
multidimensional epigenetic landscape associated with extended
pluripotency. Nucleic Acids Res. 50:12019–12038. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Huang F, Zhao H, Du Z and Jiang H: miR-615
inhibits prostate cancer cell proliferation and invasion by
directly targeting Cyclin D2. Oncol Res. 27:293–299. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Dong Q, Meng P, Wang T, Qin W, Qin W, Wang
F, Yuan J, Chen Z, Yang A and Wang H: MicroRNA let-7a inhibits
proliferation of human prostate cancer cells in vitro and in vivo
by targeting E2F2 and CCND2. PLoS One. 5:e101472010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chen X, Wu Y, Wang X, Xu C, Wang L, Jian
J, Wu D and Wu G: CDK6 is upregulated and may be a potential
therapeutic target in enzalutamide-resistant castration-resistant
prostate cancer. Eur J Med Res. 27:1052022. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yu Z, Zhan C, Du H and Zhang L, Liang C
and Zhang L: Baicalin suppresses the cell cycle progression and
proliferation of prostate cancer cells through the CDK6/FOXM1 axis.
Mol Cell Biochem. 469:169–178. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chakraborty G, Armenia J, Mazzu YZ,
Nandakumar S, Stopsack KH, Atiq MO, Komura K, Jehane L, Hirani R,
Chadalavada K, et al: Significance of BRCA2 and RB1 Co-loss in
aggressive prostate cancer progression. Clin Cancer Res.
26:2047–2064. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ku SY, Rosario S, Wang Y, Mu P, Seshadri
M, Goodrich ZW, Goodrich MM, Labbé DP, Gomez EC, Wang J, et al: Rb1
and Trp53 cooperate to suppress prostate cancer lineage plasticity,
metastasis, and antiandrogen resistance. Science. 355:78–83. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Li Y, Wang F, Xu J, Ye F, Shen Y, Zhou J,
Lu W, Wan X, Ma D and Xie X: Progressive miRNA expression profiles
in cervical carcinogenesis and identification of HPV-related target
genes for miR-29. J Pathol. 224:484–495. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
McNair C, Urbanucci A, Comstock CE,
Augello MA, Goodwin JF, Launchbury R, Zhao SG, Schiewer MJ, Ertel
A, Karnes J, et al: Cell cycle-coupled expansion of AR activity
promotes cancer progression. Oncogene. 36:1655–1668. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Oner M, Lin E, Chen MC, Hsu FN, Shazzad
Hossain Prince GM, Chiu KY, Teng CJ, Yang TY, Wang HY, Yue CH, et
al: Future aspects of CDK5 in prostate cancer: From pathogenesis to
therapeutic implications. Int J Mol Sci. 20:38812019. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zolochevska O and Figueiredo ML: Cell
cycle regulator cdk2ap1 inhibits prostate cancer cell growth and
modifies androgen-responsive pathway function. Prostate.
69:1586–1597. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Schiewer MJ, Augello MA and Knudsen KE:
The AR dependent cell cycle: Mechanisms and cancer relevance. Mol
Cell Endocrinol. 352:34–45. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Agus DB, Cordon-Cardo C, Fox W, Drobnjak
M, Koff A, Golde DW and Scher HI: Prostate cancer cell cycle
regulators: Response to androgen withdrawal and development of
androgen independence. J Natl Cancer Inst. 91:1869–1876. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Huggins C and Hodges CV: Studies on
prostatic cancer: I. The effect of castration, of estrogen and of
androgen injection on serum phosphatases in metastatic carcinoma of
the prostate. 1941. J Urol. 168:9–12. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Knudsen KE, Arden KC and Cavenee WK:
Multiple G1 regulatory elements control the androgen-dependent
proliferation of prostatic carcinoma cells. J Biol Chem.
273:20213–20222. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Lee YM and Sicinski P: Targeting cyclins
and cyclin-dependent kinases in cancer: Lessons from mice, hopes
for therapeutic applications in human. Cell Cycle. 5:2110–2114.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Malumbres M and Barbacid M: Cell cycle
kinases in cancer. Curr Opin Genet Dev. 17:60–65. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Sherr CJ and Roberts JM: Living with or
without cyclins and cyclin-dependent kinases. Genes Dev.
18:2699–2711. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Xu Y, Chen SY, Ross KN and Balk SP:
Androgens induce prostate cancer cell proliferation through
mammalian target of rapamycin activation and post-Transcriptional
increases in cyclin D proteins. Cancer Res. 66:7783–7792. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Knudsen ES and Knudsen KE: Tailoring to
RB: Tumour suppressor status and therapeutic response. Nat Rev
Cancer. 8:714–724. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Jain K, Jin CY and Clarke SG: Epigenetic
control via allosteric regulation of mammalian protein arginine
methyltransferases. Proc Natl Acad Sci USA. 114:10101–10106. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Jain K and Clarke SG: PRMT7 as a unique
member of the protein arginine methyltransferase family: A review.
Arch Biochem Biophys. 665:36–45. 2019. View Article : Google Scholar : PubMed/NCBI
|
